{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:22:27Z","timestamp":1791829347578,"version":"4.3.4"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T00:00:00Z","timestamp":1768521600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100010112","name":"Outstanding Youths Development Scheme of Nanfang Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010112","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010096","name":"Southern Medical University","doi-asserted-by":"publisher","award":["2022J002"],"award-info":[{"award-number":["2022J002"]}],"id":[{"id":"10.13039\/501100010096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Limited research exists on immune checkpoint inhibitors (ICIs)' antiviral efficacy in hepatitis B virus (HBV)\u2013related hepatocellular carcinoma (HCC). This study aimed to evaluate the impact of ICIs on multiple HBV markers and its correlation with HCC prognosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was performed on 318 HBV-related HCC patients, including 268 who received ICIs (with\/without targeted therapy; ICI group) and 50 who received targeted therapy alone (non-ICI group). Levels of quantitative HBsAg (qHBsAg), HBV DNA, HBV RNA, and HBcrAg were monitored. Tumor response was evaluated using RECIST 1.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Over a median 8.1-month follow-up, the ICI group showed a significantly greater decrease in all HBV markers. At week 96, the ICI group showed significantly higher cumulative incidences of HBsAg response (loss or \u22650.5 Log10 decline) (41.6% vs 14.9%, P = .006) and HBcrAg response (negativity or \u22651 Log10 decline) (46.3% vs 18.1%, P = .007) than non-ICI group and a significantly faster achievement rate of HBV RNA response (negativity or \u22650.5 Log10 decline) (hazard ratio [HR]: 1.80, 95% CI: 1.08\u20132.99, P = .021). Notably, the PD-1 inhibitors showed significantly better virological response efficacy than PD-L1 inhibitors (HR = 2.04\u20135.43). The patients with lower levels of HBV markers at enrollment demonstrated significantly better overall survival. Moreover, patients achieving virological response were associated with significantly better survival outcomes and tumor response, with HR ranging 1.64\u20138.06.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors demonstrate dual therapeutic effects in HBV-related HCC, significantly reducing multiple HBV markers while concurrently enhancing prognosis in combination with antiviral therapy, emphasizing the importance of sustained virological suppression for optimal HCC outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/infdis\/jiag036","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:28:48Z","timestamp":1768307328000},"page":"1015-1026","source":"Crossref","is-referenced-by-count":2,"title":["Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus\u2013Related Hepatocellular Carcinoma Patients"],"prefix":"10.1093","volume":"233","author":[{"given":"Yujie","family":"Ran","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]},{"name":"Key Laboratory of Infectious Diseases Research in South China, Ministry of Education , Guangzhou ,","place":["China"]},{"name":"Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases , Guangzhou ,","place":["China"]},{"name":"Guangdong Provincial Clinical Research Center for Viral Hepatitis , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengya","family":"Zang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyun","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]},{"name":"Key Laboratory of Infectious Diseases Research in South China, Ministry of Education , Guangzhou ,","place":["China"]},{"name":"Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases , Guangzhou ,","place":["China"]},{"name":"Guangdong Provincial Clinical Research Center for Viral Hepatitis , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingli","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaiyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]},{"name":"Key Laboratory of Infectious Diseases Research in South China, Ministry of Education , Guangzhou ,","place":["China"]},{"name":"Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases , Guangzhou ,","place":["China"]},{"name":"Guangdong Provincial Clinical Research Center for Viral Hepatitis , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabing","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5922-483X","authenticated-orcid":false,"given":"Rong","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nanfang Hospital, Southern Medical University , Guangzhou ,","place":["China"]},{"name":"Key Laboratory of Infectious Diseases Research in South China, Ministry of Education , Guangzhou ,","place":["China"]},{"name":"Guangdong Provincial Key Laboratory for Prevention and Control of Major Liver Diseases , Guangzhou ,","place":["China"]},{"name":"Guangdong Provincial Clinical Research Center for Viral Hepatitis , Guangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,16]]},"reference":[{"key":"2026061615211627100_jiag036-B1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","article-title":"Global, regional and national burden of primary liver cancer by subtype","volume":"161","author":"Rumgay","year":"2022","journal-title":"Eur J Cancer"},{"key":"2026061615211627100_jiag036-B2","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","article-title":"Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial","volume":"18","author":"Vilgrain","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026061615211627100_jiag036-B3","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (Checkmate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"2026061615211627100_jiag036-B4","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026061615211627100_jiag036-B5","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1136\/gutjnl-2025-334928","article-title":"Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction","volume":"74","author":"Pinter","year":"2025","journal-title":"Gut"},{"key":"2026061615211627100_jiag036-B6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.molimm.2020.12.004","article-title":"Enhanced antiviral benefit of combination therapy with anti-HBV and anti-PD1 gRNA\/cas9 produces a synergistic antiviral effect in HBV infection","volume":"130","author":"Zhen","year":"2021","journal-title":"Mol Immunol"},{"key":"2026061615211627100_jiag036-B7","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jhep.2024.07.018","article-title":"Functional cure of hepatitis B in patients with cancer undergoing immune checkpoint inhibitor therapy","volume":"82","author":"Mon","year":"2025","journal-title":"J Hepatol"},{"key":"2026061615211627100_jiag036-B8","doi-asserted-by":"crossref","first-page":"e1003856","DOI":"10.1371\/journal.ppat.1003856","article-title":"Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection","volume":"10","author":"Liu","year":"2014","journal-title":"PLoS Pathog"},{"key":"2026061615211627100_jiag036-B9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/biom12030470","article-title":"PD-L1 Silencing in liver using siRNAs enhances efficacy of therapeutic vaccination for chronic hepatitis B","volume":"12","author":"Bunse","year":"2022","journal-title":"Biomolecules"},{"key":"2026061615211627100_jiag036-B10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000534535","article-title":"Possibility of PD-1\/PD-L1 inhibitors for the treatment of patients with chronic hepatitis B infection","volume":"42","author":"Su","year":"2024","journal-title":"Dig Dis"},{"key":"2026061615211627100_jiag036-B11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jhepr.2019.06.001","article-title":"HBeAg seroconversion is associated with a more effective PD-L1 blockade during chronic hepatitis B infection","volume":"1","author":"Ferrando-Martinez","year":"2019","journal-title":"JHEP Rep"},{"key":"2026061615211627100_jiag036-B12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J Hepatol"},{"key":"2026061615211627100_jiag036-B13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/hep.29463","article-title":"Hepatitis B virus pregenomic RNA in hepatocellular carcinoma: a nosological and prognostic determinant","volume":"67","author":"Halgand","year":"2018","journal-title":"Hepatology"},{"key":"2026061615211627100_jiag036-B14","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.cgh.2022.06.018","article-title":"Serum HBcrAg and hepatocellular carcinoma in a Taiwanese population seronegative for HBsAg and anti-HCV","volume":"21","author":"Hsieh","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061615211627100_jiag036-B15","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jcv.2011.04.005","article-title":"A comparison of two assays for quantification of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"51","author":"Sonneveld","year":"2011","journal-title":"J Clin Virol"},{"key":"2026061615211627100_jiag036-B16","doi-asserted-by":"crossref","first-page":"250","DOI":"10.4103\/2319-4170.143485","article-title":"Comparison of the elecsys HBsAg II assay and the architect assay for quantification of hepatitis B surface antigen in chronic hepatitis B patients","volume":"38","author":"Liao","year":"2015","journal-title":"Biomed J"},{"key":"2026061615211627100_jiag036-B17","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: a pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J Hepatol"},{"key":"2026061615211627100_jiag036-B18","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1097\/HEP.0000000000001006","article-title":"A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally suppressed patients with chronic hepatitis B who are HBeAg-negative","volume":"81","author":"Qian","year":"2025","journal-title":"Hepatology"},{"key":"2026061615211627100_jiag036-B19","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jhep.2024.03.046","article-title":"JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2","volume":"81","author":"Agarwal","year":"2024","journal-title":"J Hepatol"},{"key":"2026061615211627100_jiag036-B20","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41591-021-01513-4","article-title":"Safety, tolerability and antiviral activity of the antisense oligonucleotide bepirovirsen in patients with chronic hepatitis B: a phase 2 randomized controlled trial","volume":"27","author":"Yuen","year":"2021","journal-title":"Nat Med"},{"key":"2026061615211627100_jiag036-B21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cgh.2024.07.024","article-title":"Role of early on-treatment Serum HBV RNA declines in predicting hepatocellular carcinoma risk in patients with chronic hepatitis B","volume":"23","author":"Liu","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026061615211627100_jiag036-B22","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.2147\/IJGM.S321253","article-title":"Hepatitis B core-related antigen is a biomarker for off-treatment relapse after long-term nucleos(t)ide analog therapy in patients with chronic hepatitis B","volume":"14","author":"Liao","year":"2021","journal-title":"Int J Gen Med"},{"key":"2026061615211627100_jiag036-B23","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/j.jhep.2014.07.005","article-title":"Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation","volume":"61","author":"Bengsch","year":"2014","journal-title":"J Hepatol"},{"key":"2026061615211627100_jiag036-B24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","article-title":"Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape","volume":"18","author":"Jiang","year":"2019","journal-title":"Mol Cancer"},{"key":"2026061615211627100_jiag036-B25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00262-022-03254-w","article-title":"Association of hepatitis B virus DNA levels with overall survival for advanced hepatitis B virus-related hepatocellular carcinoma under immune checkpoint inhibitor therapy","volume":"72","author":"An","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"2026061615211627100_jiag036-B26","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1186\/s12879-022-07602-0","article-title":"Interaction between baseline HBV loads and the prognosis of patients with HCC receiving anti-PD-1 in combination with antiangiogenic therapy undergoing concurrent TAF prophylaxis","volume":"22","author":"Hu","year":"2022","journal-title":"BMC Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiag036\/66423858\/jiag036.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/6\/1015\/66423858\/jiag036.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/233\/6\/1015\/66423858\/jiag036.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:21:25Z","timestamp":1781637685000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/233\/6\/1015\/8426648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,16]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,1,16]]},"published-print":{"date-parts":[[2026,6,16]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiag036","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,15]]},"published":{"date-parts":[[2026,1,16]]}}}